The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.
A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.
Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect